Selecta Biosciences, Inc. (NASDAQ:SELB) Director Timothy A. Springer bought 57,598 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average price of $9.27 per share, with a total value of $533,933.46. Following the purchase, the director now owns 461,349 shares in the company, valued at $4,276,705.23. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of Selecta Biosciences, Inc. (SELB) traded up $0.89 during trading on Friday, hitting $10.23. The stock had a trading volume of 476,993 shares, compared to its average volume of 110,778. Selecta Biosciences, Inc. has a 12 month low of $8.70 and a 12 month high of $28.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 9.48 and a current ratio of 9.48.

ILLEGAL ACTIVITY NOTICE: “Selecta Biosciences, Inc. (SELB) Director Timothy A. Springer Purchases 57,598 Shares of Stock” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/17/selecta-biosciences-inc-selb-director-timothy-a-springer-purchases-57598-shares-of-stock.html.

A number of analysts have commented on SELB shares. Canaccord Genuity set a $25.00 price objective on Selecta Biosciences and gave the stock a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research upgraded Selecta Biosciences from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Saturday, November 11th. UBS AG cut Selecta Biosciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. Finally, ValuEngine cut Selecta Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $25.20.

Large investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors increased its position in Selecta Biosciences by 224.5% during the second quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock worth $131,000 after buying an additional 4,561 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Selecta Biosciences during the first quarter worth approximately $211,000. The Manufacturers Life Insurance Company increased its position in Selecta Biosciences by 827.0% during the second quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock worth $224,000 after buying an additional 10,040 shares during the last quarter. Rhumbline Advisers acquired a new position in Selecta Biosciences during the second quarter worth approximately $239,000. Finally, New York State Common Retirement Fund increased its position in Selecta Biosciences by 184.0% during the second quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock worth $248,000 after buying an additional 8,099 shares during the last quarter. 53.03% of the stock is currently owned by institutional investors and hedge funds.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Insider Buying and Selling by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Stock Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related stocks with our FREE daily email newsletter.